TFF Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company whose business has historically centered on its proprietary Thin Film Freezing (TFF) platform. The company was formed as a Delaware corporation on January 24, 2018, using intellectual property and other assets contributed from Lung Therapeutics. Its core thesis has been to create improved drug formulations for poorly soluble compounds, with particular emphasis on inhaled and dry-powder delivery formats that may enhance solubility, bioavailability, and pharmacokinetic performance. The company’s operating footprint has been associated over time with Austin and Fort Worth, Texas, and later Foxboro, Massachusetts in the context of its wind-down and planned deregistration. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm?utm_source=openai)) From a business-model standpoint, TFFP has not been a commercial pharmaceutical company but rather a platform-driven development story. Its main programs have included dry-powder inhalation formulations such as TFF VORI (voriconazole) and TFF TAC (tacrolimus), both aimed at respiratory or transplant-related applications. The company has also extended the platform into broader respiratory research, including a collaboration with the National Institute of Environmental Health Sciences to develop dry-powder hyaluronan formulations for respiratory diseases. That collaboration underscores management’s intent to position TFF as a formulation-enabling technology with potential for licensing and strategic partnerships, rather than relying solely on internal product commercialization. ([nasdaq.com](https://www.nasdaq.com/press-release/tff-pharmaceuticals-enters-into-crada-with-the-national-institute-of-environmental?utm_source=openai)) TFF Pharmaceuticals listed on the Nasdaq Capital Market in October 2019 under the ticker TFFP. Over time, the company issued clinical updates, reported preclinical data supporting its aerosol delivery approach, and completed equity financings to support operations. In 2024 it completed additional capital raises, consistent with the cash-intensive nature of early-stage biotech development. However, the most important recent corporate event came in February 2025, when TFF announced that it had notified Nasdaq of its intent to voluntarily delist and stated that this action was tied to a planned liquidation and dissolution of the company, with no alternative listing venue arranged. For investors, this means TFFP should no longer be viewed as a standard growth biotech listed on a major US exchange, but rather as a company in terminal restructuring phase. ([nasdaq.com](https://www.nasdaq.com/press-release/tff-pharmaceuticals-announces-delisting-nasdaq-and-potential-sec-deregistration-2025?utm_source=openai)) In competitive terms, TFFP occupied a specialized niche in inhaled dry-powder formulation science. Its competitive advantage was the TFF technology itself, which the company believed could create differentiated drug-delivery profiles. At the same time, the company faced the typical constraints of clinical-stage biotech: no approved products, no meaningful commercial revenue base, and ongoing dependence on external capital and partnership execution. The recent corporate narrative is therefore dominated less by pipeline expansion than by financing, strategic advisory work on partnerships and licensing, and ultimately the delisting and wind-down announcement. For market participants, the key takeaway is that TFF Pharmaceuticals was an innovation-led biotech issuer on the Nasdaq in the United States, but one that moved into liquidation mode in 2025. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1733413/000121390024027185/ea0201339-10k_tffpharma.htm?utm_source=openai))